返回
Ascentage Pharma Group International（6855.HK）價格
6855.HK 股價走勢圖
ASCENTAGE-B (6855.HK)
Ascentage Pharma Group International
HK$48.1
-1.75%
$-0.85
休市： Jan 30, 16:00:00 HKT
Earnings FAQ
6855.HK 最近的每股盈餘與預期相比如何？
Ascentage Pharma Group International 6855.HK 上一季度的收入表現如何？
Ascentage Pharma Group International 的收入預期是多少？
Ascentage Pharma Group International 的盈利品質評分是多少？
Ascentage Pharma Group International 何時發布財報？
Ascentage Pharma Group International 的預期收益是多少？
Ascentage Pharma Group International 是否超出收益預期？
關鍵數據
前收市價
$49.04
開盤價
$48.96
當日範圍
$47.6 - $50
52週區間
$31.35 - $95.35
交易量
2.1M
平均成交量
1.9M
每股盈餘 (TTM)
-4.01
股息收益率
--
市值
$17.8B
什麼是 ASCENTAGE-B？
Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. The company is headquartered in Suzhou, Jiangsu and currently employs 605 full-time employees. The company went IPO on 2019-10-28. The firm's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The firm's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The firm primarily conducts its businesses in domestic market.